Overview

Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Status:
Recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

Phase:

Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Collaborator:

Memorial Sloan Kettering Cancer Center

Treatments:

Crizotinib